Collect Product
Product Details
Synonyms
FAP, FAPalpha, SIMP, Seprase, APCE
Source
PE-Labeled Human FAP, His Tag (FAP-HP245) is produced via site-specific conjugation of PE to Human FAP, His Tag under optimal conditions with a proprietary technology. Human FAP, His Tag is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Asp 760 (Accession # Q12884-1).
Predicted N-terminus: His
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 93.1 kDa.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Application
Please note that this product is NOT compatible to streptavidin detection system.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Bioactivity-FACS
5e5 of anti-FAP CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human FAP, His Tag (Cat. No. FAP-HP245) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Protocol
User Reviews Publish Comment
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Prolyl endopeptidase FAP
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
88 Details
- Highest R&D Stage：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
